A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma
Latest Information Update: 25 Sep 2025
At a glance
- Drugs DZ-002 (Primary)
- Indications Lymphoma; Pancreatic cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Da Zen Theranostics
Most Recent Events
- 22 Aug 2025 Status changed from active, no longer recruiting to completed.
- 05 Feb 2025 Planned End Date changed from 1 Mar 2025 to 1 Apr 2025.
- 05 Feb 2025 Status changed from recruiting to active, no longer recruiting.